author-photo

Heinz Lubenau

17

Papers

120

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: Safety run-in results—NCT03750071.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B196: Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
P01.031 VXM01 phase I study in patients with progressive glioblastoma - final results

2018 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
VXM01, an oral T-cell vaccine targeting the tumor vasculature: Results from a randomized, controlled, first-in-man study in pancreatic cancer patients.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 4558: Immunogenicity and antitumor efficacy of live attenuatedSalmonellatyphimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

2017 OncoImmunology
Show All
- Source
- Cite
- Save
Citations (18)
VXM01 phase I study in patients with resectable progression of a glioblastoma.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGF-receptor 2, in patients with advanced pancreatic cancer.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)